In The News

In The News

Biocompare | August 24, 2017
Using an immune-related molecule, usually an antibody, to measure an analyte in a sample makes up the basics of an immunoassay. The best-known version is the enzyme-linked immunosorbent assay (ELISA).
DDN News | August 2017
The study, entitled “Polymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays: Detection of drug-induced liver injury,” is a proof-of-concept paper showing how the scientists combined Quanterix’s Single Molecule Array Detection technology, or Simoa, and…
Modern Life Network: Tech of Sports | August 2, 2017
Quanterix CEO Kevin Hrusovsky sits down with Rick Limpert, host of Tech of Sports by Modern Life Network, to look current concussion detection methods and why many of them fail; and a new test that can dramatically change the game and improve player safety.
Genetic Engineering and Biotechnology News | July 26, 2017
Improved Cancer Immunodiagnostics and Immunotherapeutics Depend on Biomarker Discovery
GenomeWeb| July 18, 2017
NEW YORK (GenomeWeb) – A team of investigators from Quanterix, Destina Genomics, and the University of Edinburgh have developed a new approach for the amplification-free detection of microRNA-122, a biomarker used for diagnosing liver toxicity.
CLP | July 11, 2017
Quanterix Corp, Lexington, Mass, has launched the Simoa Neurology 4-Plex A assay (N4PA).
Drug Discovery & Development News | July 11, 2017
Published jointly by Quanterix, DestiNA Genomics Ltd., Edinburgh University and the Pfizer-Universidad de Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENyO), the study, titled, “Polymerase-free measurement of microRNA-122 with single base specificity using single…
Neurology Advisor | June 6, 2017
Levels of neurofilament light chain (NfL) in cerebrospinal fluid (CSF) and plasma can help predict the rate of disease progression in patients with progressive supranuclear palsy (PSP). Results of the study were presented at the 2017 International Congress of Parkinson's Disease and Movement…
SportTechie| May 17, 2017
Simoa is considerably advancing the study of concussions because researchers are using it to detect biomarkers — proteins whose concentrations can be indicative of TBI — that were previously undetectable. The most well-known of these concussion biomarkers is a protein called tau.
Clinical Lab Products | May 2017
Our ultra-sensitive Simoa platform and complete assay kits were featured in this month’s issue of Clinical Lab Products magazine. View our listing on page 26